日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Antibody responses to SARS-CoV-2 variants LP.8.1, LF.7.1, NB.1.8.1, XFG, and BA.3.2 following KP.2 monovalent mRNA vaccination

接种KP.2单价mRNA疫苗后,针对SARS-CoV-2变异株LP.8.1、LF.7.1、NB.1.8.1、XFG和BA.3.2的抗体反应

Abbad, Anass; Lerman, Brian; Ehrenhaus, Jordan; Monahan, Brian; Singh, Gagandeep; Wilson, Adria; Slamanig, Stefan; Aracena, Ashley; Lyttle, Neko; Nardulli, Jessica R; Farrugia, Keith; Khalil, Zain; Gonzalez-Reiche, Ana Silvia; Sordillo, Mia Emilia; Sun, Weina; van Bakel, Harm; Simon, Viviana; Krammer, Florian

Mapping of human monoclonal antibody responses to XBB.1.5 COVID-19 monovalent vaccines: a B cell analysis

XBB.1.5 COVID-19 单价疫苗的人类单克隆抗体反应图谱:B 细胞分析

Fantin, Raianna F; Clark, Jordan J; Cohn, Hallie; Jaiswal, Deepika; Bozarth, Bailey; Rao, Vishal; Civljak, Alesandro; Lobo, Igor; Nardulli, Jessica R; Srivastava, Komal; Yong, Jeremy S; Andreata-Santos, Robert; Bushfield, Kaitlyn; Lee, Edward S; Singh, Gagandeep; Kleinstein, Steven H; Krammer, Florian; Simon, Viviana; Bajic, Goran; Coelho, Camila H

XBB.1.5 monovalent vaccine induces lasting cross-reactive responses to SARS-CoV-2 variants such as HV.1 and JN.1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific antibodies.

XBB.1.5 单价疫苗可诱导对 SARS-CoV-2 变种(如 HV.1 和 JN.1)以及 SARS-CoV-1 的持久交叉反应,但产生的 XBB.1.5 特异性抗体有限

Carreño Juan Manuel, Lerman Brian, Singh Gagandeep, Abbad Anass, Yellin Temima, Ehrenhaus Jordan, Fried Miriam, Nardulli Jessica R, Kang Hyun Min, Mulder Lubbertus C F, Gleason Charles, Srivastava Komal, Simon Viviana, Krammer Florian